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Objective: To compare the clinical value of uterine artery embolization (UAE) with local methotrexate
(MTX) infusion to embolization without MTX in the treatment of cesarean scar pregnancies (CSPs).
Materials and methods: From January 2009 to December 2013, 50 patients with CSP treated with UAE
receiving or not receiving local MTX infusion prior to curettage were analyzed retrospectively. Twenty-
two patients were offered UAE with local MTX infusion prior to curettage (UAE þ MTX group), whereas
28 patients received UAE alone prior to curettage (UAE group). Clinical data and the outcomes were
analyzed, followed by a brief review of the published literature summarizing what is known about UAE
with and without MTX for the treatment of CSP.
Results: UAE was successful in 42 of 50 cases (84%), with complications occurring in only ﬁve patients.
There were no signiﬁcant differences in the success rate, complication rate, recovery time, or hospital-
ization costs between the UAE þ MTX group and the UAE group. However, blood loss in the UAE þ MTX
group was signiﬁcantly higher than in the UAE group.
Conclusion: UAE with or without local MTX infusion might be an effective treatment for CSP. Compared
with UAE alone, UAE with local MTX infusion did not dramatically improve the therapeutic effect of UAE.
A larger and more comprehensive random control study is warranted to better evaluate the therapeutic
effects of UAE in the treatment of CSP.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Cesarean scar pregnancy (CSP) is a rare but potentially life-
threatening complication of a previous cesarean birth, in which
the gestational sac is implanted at the site of the previous cesarean
scar and is surrounded by uterine muscular ﬁber, scar tissue, and
the thin myometrium adjacent to the bladder [1,2]. CSP may lead to
excessive hemorrhaging, shock, and/or uterine rupture with the
potential necessity for hysterectomy; in the worst case, CSP can
result inmaternal death [3,4]. Therefore, it is imperative that CSP be
diagnosed and effectively treated as early as possible. The number
of identiﬁed CS pregnancies ranges from 1/1800 to 1/2216 of every
pregnancy [5,6], and is likely to exponentially rise in the near
future, because of the increasing rate of cesarean deliverygy and Obstetrics, Taizhou
ou Medical College, Number
China.
bstetrics & Gynecology. Publishedworldwide and enhanced detection through the widespread use of
transvaginal ultrasound [7,8].
However, to date, the optimal management of CSP remains to be
determined. In this study, the clinical value of uterine artery
embolization (UAE) with or without local methotrexate (MTX)
infusion prior to curettage in the treatment of CSP are discussed,
along with a brief review of the published literature on the man-
agement of CSP.
Materials and methods
Patients
This study, which was approved by the Ethics Committee of
Taizhou Hospital of Zhejiang Province, Zhejiang, China is a retro-
spective case series of 50 patients diagnosed with CSP treated over
a period of 5 years (from January 2009 to December 2013). Patients
with a ruptured uterus, inevitable abortion, active inﬂammation,
severe cardiac, lung, kidney, or liver disease, or allergy to iodinated
contrast medium, MTX, or embolic material were excluded. Allby Elsevier Taiwan LLC. All rights reserved.
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consent was obtained from participants prior to the treatment. The
medical records and ultrasound images of all patients with CSP
were collected from the original hospital charts, operation notes,
and outpatient medical records via telephone questionnaires.
The average patient age was 31.68 ± 4.58 years (range 22e40
years). The average time between CSP and previous cesarean de-
livery was 4.87 ± 3.04 years (range 0.6e12 years). In terms of the
number of cesarean deliveries prior to CSP, 38 patients had one, 11
patients had two, and one patient had three. The range of symp-
toms was wide. Twenty-six patients complained of intermittent
slight vaginal bleeding, in which ﬁve cases were transferred to our
hospital because of a failed artiﬁcial abortion, and nine cases suf-
fered from excessive vaginal hemorrhage owing to misdiagnosis
and underwent dilatation and curettage (D&C) or medical abortion
prior to referral from another hospital. Three patients only expe-
rienced light abdominal discomfort, and 12 were asymptomatic.
Diagnosis
Alongside a positive pregnancy test, CSP was conﬁrmed by the
following transvaginal ultrasound criteria [9e11]: (1) an empty
uterine cavity without contact with the sac, (2) a clearly visible
empty cervical canal without contact with the sac, (3) the presence
of the gestational sac in the anterior uterine isthmus with or
without a fetal pole or fetal cardiac activity (depending on the
gestational age), and (4) an absent or diminished myometrial layer
between the bladder and the sac (Figure 1).
Procedure
UAE with or without local MTX infusion before curettage was
performed. A right transfemoral approach was used for artery ac-
cess, and the uterine artery was selectively catheterized with a 5F
Yashiro catheter (TERUMO, Tokyo, Japan) and embolized with gel-
foam sponge particles (1e2 mm in diameter), with or without
25 mg of MTX infused bilaterally into via each uterine artery for a
total of 50 mg prior to the embolization procedure. Uterine artery
angiogramwas performed prior to and after UAE. Embolizationwas
performed until the bilateral uterine arteries were occluded
(Figure 2). Curettage was performed under the guidance of
abdominal ultrasound 24e120 hours later by qualiﬁed doctors.
Treatment assessment and follow-up
The dynamic levels of serum b-human chorionic gonadotropin
(b-hCG) were determined every 3 days until the level had
decreased by > 50% from pretherapy levels, thenweekly until levelsFigure 1. Transvaginal ultrasound image of a cesarean scar pregnancy at 7 postmenstrual
Triangular shape of the sac; the embryonic pole and fetal cardiac activity are visible (arrow)
the sac and bladder.returned to normal. Ultrasound was used to monitor the size of the
gestational mass weekly until serum b-hCG had returned to normal
levels, thenmonthly until the mass had disappeared. The outcomes
of subsequent patient reproduction were recorded. Failure of the
initial treatment was considered in the case of complications, such
as signiﬁcant vaginal bleeding (blood loss > 200 mL), when 7th day
serum b-hCG continued to rise or decreased by  50%, or when the
gestational mass became larger than pretherapy levels. In these
cases, additional therapies were given. All patients were asked not
to have intercourse until termination of the CSP was conﬁrmed.
Data analysis
Mean ± standard deviation (c ± S) is presented for continuous
and ordinal data, and categorical data are presented as the absolute
count and percentage. The Chi-square test was used to compare
categorical data. The two-sample t test was used to compare
continuous and ordinal data. SPSS 19.0 software (SPSS Inc., Chicago,
IL, USA) was used for statistical analysis. A p value < 0.05 was
considered statistically signiﬁcant.
Results
Fifty patients underwent UAE with or without local MTX infu-
sion prior to curettage. This was successful in 42 cases (84%); eight
cases required additional treatments with complications occurring
in ﬁve cases; four of them were complicated with severe vaginal
bleeding during curettage and were given hysterotomy. Post-
operative pathologic examination of excised CSP specimens from
these four patients showed clusters of trophoblast cells invading
the myometrium. One patient's gelatin sponge separated from the
uterine artery and embolized the right leg after UAE. Therefore, this
patient went to other hospitals in Shanghai, China for a second UAE
upon request. In the remaining three cases, treatments were
considered a failure: In the ﬁrst case, the patient was given an
additional intra-amniotic MTX injection (50 mg) and later a second
D&C. In the second case, the patient underwent systemic MTX
treatment (50 mg/m2) and later another D&C. In the third case, the
patient underwent hysterotomy after extensive counseling.
Among the 50 patients, 22 patients were offered UAE combined
with local MTX infusion prior to curettage (UAE þMTX group), and
28 patients received UAE only prior to curettage (UAE group). The
clinical characteristics and ﬁndings of the two groups are presented
in Table 1.
There was no signiﬁcant difference in the serum b-HCG levels,
gestational age, diameter of the sac, or myometrium thickness
between the two groups. In the UAEþMTX group, 77.3% cases were
successfully treated, representing a lower success rate than in theweeks. (A) Empty uterine cavity with gestational sac between cavity and cervix. (B)
. (C) Gestational sac embedded in the scar; thin (3 mm) myometrium (arrow) between
Figure 2. (A, B) Uterine artery angiography prior to uterine artery embolization (UAE). (C, D) Arterial embolization was conﬁrmed after UAE.
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group was higher than in the UAE group (18.2% vs. 3.6%). The time
of recovery in the UAE þ MTX group was shorter than that in the
UAE group, whereas hospitalization costs were higher in the
UAE þ MTX group than in the UAE group. However, these differ-
ences were not statistically signiﬁcant (p > 0.05). The amount of
bleeding in the UAE þ MTX group was signiﬁcantly higher than in
the UAE group. This might be accounted for by the four cases that
suffered from excessive vaginal hemorrhage in the UAE þ MTX
group.
During the long-term follow-up, we lost contact with four pa-
tients. In the remaining 46 women, the average time of recovery
was 35.49 ± 15.60 days, whereas the recovery of menstruation was
20e45 days. Most patients who underwent therapy indicated that
they no longer wished to conceive. Four cases did conceive againTable 1
Clinical characteristics and ﬁndings of women with CSP treated with UAE with or witho
Characteristic UAE þ MTXa group
No. of cases 22
Serum b-hCG (U/L) 45,710.14 ± 58,538.86
Gestational age (d) 59.86 ± 17.67
Diameter of the sac (mm) 28.56 ± 16.99
Thickness of myometrium (mm) 3.22 ± 1.57
Success rate (%) 77.3 (17/22)
Complication rate (%) 18.2 (4/22)
Hospitalization cost (yuan) 8582.13 ± 3101.72
Time of recovery (d) 31.18 ± 14.80
Amount of bleeding (mL) 80.25 ± 113.92
b-hCG ¼ b-human chorionic gonadotropin; CSP ¼ cesarean scar pregnancy; MTX ¼ met
a UAE with local MTX infusion prior to curettage.
b UAE alone prior to curettage.and underwent artiﬁcial abortion. One patient developed an
ectopic pregnancy and received laparoscopic ipsilateral salpingec-
tomy. There were no cases of CSP recurrence.
Discussion
UAE prior to curettage is currently accepted as an effective
treatment for CSP, and it is also usually used to control acute
bleeding [12,13]. UAE has a number of advantages [14e16]. First, it
blocks the blood supply of the gestational sac, which causes embryo
ischemia, hypoxia, and ﬁnally atrophy and necrosis, and at the same
time reduces the risk of bleeding during curettage. Second, in the
case of excessive bleeding, UAE can accurately detect and embolize
the pelvic arteries to stop bleeding. Third, as an embolic agent,
gelatin sponge can embolize arteries effectively, while at the sameut MTX prior to curettage.
UAEb group p
28 d
38,347.06 ± 42,500.99 0.663
54.33 ± 17.51 0.279
27.73 ± 12.30 0.88
2.35 ± 1.48 0.166
89.3 (25/28) 0.223
3.6 (1/28) 0.109
7212.98 ± 1918.13 0.061
39.00 ± 15.62 0.081
32.04 ± 21.41 0.036
hotrexate; UAE ¼ uterine artery embolization.
Table 2
Published reports of cesarean scar pregnancy treated with UAE grouped by initial treatment strategy.
Reference Period of case
collection
No. of
cases
Initial treatment modalities useda Additional
treatment
needed
Hysterectomy or
supracervical
hysterectomy performed
UAE þ MTX
Wu et al [17] 2009e2012 6 UAE þ MTX þ Intramuscular MTX (n ¼ 2);
UAE þ MTX þ Intramuscular MTX to D&C (n ¼ 4)
0 0
An et al [18] 2010e2012 23 UAE þ MTX 7 4
Wang et al [19] 2007e2012 128 UAE þ MTX to D&C 15 5
Lan et al [12] 2004e2010 79 UAE þ MTX to D&C 0 0
Le et al [20] 2008e2012 10 UAE þ MTX to D&C 0 0
Zhang et al [16] 2009e2012 11 UAE þ MTX to D&C 1 0
Shen et al [21] 2008e2010 46 UAE þ MTX to suction curettage (n ¼ 36); UAE þ MTX (n ¼ 10) 1 1
Wu et al [22] 2000e2010 22 UAE þ MTX (n ¼ 6); UAE þ MTX to D&C (n ¼ 16) 0 0
Yin et al [23] 2002e2008 13 UAE þ MTX to vacuum aspiration 1 0
Li et al [24] 2002e2009 31 UAE þ MTX to D&C 5 0
Shao et al [25] 2003e2010 32 UAE þ MTX to D&C (n ¼ 26); UAE þ MTX (n ¼ 6) 2 0
Liang and He [26] 2005e2009 42 UAE þ MTX to D&C 0 0
Zhang et al [27] 2005e2008 60 UAE þ MTX to D&C 0 0
Yang et al [28] 2003e2008 38 UAE þ MTX (n ¼ 14); UAE þ MTX to D&C (n ¼ 24) 4 0
Yin et al [29] 2003e2008 30 UAE þ MTX to D&C (n ¼ 13) 0 0
Present study 2009e2013 50 UAE þ MTX to D&C (n ¼ 22) 5 0
UAE
Cao et al [30] 2007e2012 54 UAE to D&C (n ¼ 52); UAE (n ¼ 2) 0 0
Wu et al [31] 2012 1 UAE þ intramuscular MTX 1 1
Kochhar et al [32] 2012 1 UAE þ intramuscular MTX 0 0
Yu et al [33] 2003e2011 56 UAE to D&C 2 0
Li et al [34] 2004e2010 12 UAE to endoscopy 0 0
Sadeghi et al [35] 2007e2008 1 UAE þ systemic MTX 1 1
Yin et al [29] 2003e2008 30 UAE to D&C (n ¼ 17); 0 0
Zhuang and Huang [36] 2003e2007 37 UAE to D&C 3 0
Hois et al [37] 2006 1 UAE þ intramuscular MTX 0 0
Yan [38] 2006 1 UAE þ intra-amniotic MTX 0 0
Sugawara et al [39] 2005 3 UAE þ intra-amniotic MTX 3 0
Chou et al [40] 2003 1 UAE 0 0
Yang and Jeng [41] 2003 1 UAE þ laparotomy 0 0
Ghezzi et al [42] 2001 1 UAE þ Systemic MTX þ intra-amniotic KCl 0 0
Marcus et al [43] 1999 1 UAE þ systemic MTX 1 1
Present study 2009e2013 50 UAE to D&C (n ¼ 28) 3 0
D&C ¼ dilatation and curettage; MTX ¼ methotrexate; KCl ¼ potassium chloride; UAE ¼ uterine artery embolization.
a “to” indicates subsequent inventions; “þ” indicates concurrent interventions.
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ﬂow of the uterus can recover and uterine function is not affected.
To better compare the value of UAE with or without MTX in the
treatment of CSP, we performed a brief review of the published
literature from 1995 to 2014 via the MEDLINE/PubMed database,
searching the terms “cesarean scar pregnancy” and “uterine artery
embolization/embolism.” To identify additional articles and case
reports, the secondary references of these publications were also
reviewed.We identiﬁed 44 articles, 29 of which involved UAE in the
treatment of CSP and were included, as shown in Table 2
[12,16e43].
A total of 792 cases were identiﬁed and analyzed based on
their initial management and outcome (Table 3). Among the 792
cases, only 55 cases (6.94%) required additional treatment(s), and
the uterus was preserved in 779 patients (98.36%). Overall, ac-
cording to these ﬁndings, UAE might be an effective and safe
treatment for CSP.Table 3
Outcome of all reported cases of cesarean scar pregnancy.
Initial treatment Total no. of cases Additio
UAE þ MTX 576 41 (7.12
UAE 216 14 (6.48
Total 792 55 (6.94
* p > 0.05, compared to UAE þ MTX.
MTX ¼ methotrexate; UAE ¼ uterine artery embolization.MTX has been used widely as a ﬁrst-line conservative drug in
the treatment of tubal pregnancy. UAE combined with local MTX
infusion has been used extensively in recent years, and it has been
suggested that the effects of MTX are synergistic to UAE
[17,25,30,35e37,39]. However, in our review of the current litera-
ture, although UAE þMTX was used in 576 patients, and UAE alone
was used in 216 patients in the treatment of CSP, there were no
signiﬁcant differences in the occurrence of additional treatment or
hysterectomy between the two groups. Therefore, we propose that
the addition of MTX does not improve the therapeutic outcomes of
UAE; in fact, it may actually increase the risk for complications
related to bleeding.
In conclusion, based on the present results and a review of the
literature, UAE with or without local MTX infusion prior to curet-
tage might be an effective treatment for CSP. UAE can be used to
block the blood supply to the uterus to reduce the risk of bleeding
during curettage. Compared with UAE alone, UAE with local MTXnal treatment needed, n (%) Hysterectomy or supracervical
hysterectomy performed, n (%)
) 10 (1.74)
)* 3 (1.39)*
) 13 (1.64)
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support the use of MTX in the treatment of CSP. However, this study
has its limitations. First, it is a retrospective study with a small
sample population, which reduces the overall robustness of this
approach. Second, this study does not assess the potential effect of
MTX dose or speciﬁc patient characteristics on the overall outcome.
In addition, our study did not take into account the number of deep
implantations, or the viability of the fetus inside the sac prior to
therapy, which can affect the treatment of CSP and increase the risk
of complication or the failure to resolve the condition. A larger
random control study is therefore warranted in a larger patient
population affected by CSP.
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